| Document |
Document Title |
|
WO/2020/137921A1 |
The present invention provides an actinic light sensitive or radiation sensitive resin composition, a resist film, a pattern forming method, and an electronic device production method, wherein the actinic light sensitive or radiation sen...
|
|
WO/2020/130528A1 |
The present specification relates to a compound of chemical formula 1 and an organic light emitting diode comprising same.
|
|
WO/2020/130327A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2020/127145A2 |
The invention relates to materials for use in electronic devices, to methods for producing said materials, and to electronic devices containing said materials.
|
|
WO/2020/130511A1 |
The present specification pertains to: a compound of chemical formula 1; and an organic light-emitting device including same.
|
|
WO/2020/127259A2 |
The present application concerns compounds for use in electronic devices, processes for preparing the compounds, and electronic devices comprising the compounds.
|
|
WO/2020/127960A1 |
The present invention relates to disubstituted alkyne derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
|
|
WO/2020/129466A1 |
The present invention provides: a method for producing a crystal of a cyclohexane tricarboxylic acid anhydride, by which a crystal having a little amount of liquid in the surface is able to be obtained; and a crystal. A method for produc...
|
|
WO/2020/125993A1 |
The present invention primarily relates to the use of a compound according to the general formula (I) wherein i) m is 1, n is 1, o is 0 or 1, Y is Hydrogen, or ii) m is 2, n is 0, o is 1, Y is methyl, and wherein X is O or methylene, R a...
|
|
WO/2020/127176A1 |
The present application concerns compounds for use in electronic devices, processes for preparing the compounds, and electronic devices comprising the compounds.
|
|
WO/2020/130623A1 |
The present specification provides a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2020/125911A1 |
The present invention relates to the use of a new germacranolide-type sesquiterpene lactone (II), isolated from the species endemic to the island of Hispaniola, Koanophyllon gibbosum (synonym Eupatorium gibbosum), in the preparation of a...
|
|
WO/2020/122671A1 |
The present specification relates to a compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2020/123792A1 |
The present disclosure includes compositions and methods for improved DNA amplification reactions. In particular, the present disclosure provides compositions and methods for hot-start PCR applications using DNA polymerase inhibitors tha...
|
|
WO/2020/120835A1 |
According to an example aspect of the present invention, there is provided both a continuous method and a batch method for producing furandicarboxylic acid (FDCA) and furandicarboxylic acid ester (FDCAE) from aldaric acid ester by utiliz...
|
|
WO/2020/123488A1 |
The present disclosure provides crystalline Form II of nicotinic acid riboside, crystalline Form II of nicotinic acid riboside triacetate, and methods of preparation thereof. In an embodiment, the present disclosure relates to crystallin...
|
|
WO/2020/119772A1 |
Provided is a mefuparib hydrochloride polymorphic substance and a preparation method therefor and an application thereof. Specifically, provided is four crystal forms, i.e., D, E, F, and G, of 2-[4-(methylaminomethyl)phenyl]-5-fluorine-b...
|
|
WO/2020/118206A1 |
A series of butenolide heterodimers were found to be inhibitors of the cGAS/STING pathway. They can be useful in therapies for treating a range of chronic interferon (IFN) associated autoimmune diseases and inflammation.
|
|
WO/2020/118113A1 |
Described herein are crystalline forms of (3,5-dibromo-4-hydroxyphenyl)(2-(1-hydroxyethyl)benzofuran-3
-yl-4,5,6,7-d 4)methanone, and solvates thereof.
|
|
WO/2020/117517A1 |
A polymer is made from polymerization of CBDA monomers. The resulting polymer is thermally cleavable, making it recyclable when heated and degraded. The resulting intermediate material can be hydrolyzed back to initial starting material ...
|
|
WO/2020/117366A2 |
A composition of matter including two optionally substituted phenol or optionally substituted aniline units separated by a furan spacer has been prepared. In particular, the chemical structure has a novolac bridge between the central fur...
|
|
WO/2020/113995A1 |
Provided is a method for preparing levulinic acid and furfural by means of the direct liquefaction of a fibrous biomass. The method comprises using the fibrous biomass as a raw material, mixing same with a sulfate catalyst in a polar apr...
|
|
WO/2020/116418A1 |
A compound represented by formula (1). (In the formula, R1-R4 and L1-L4 are as defined in the description; Ar represents a moiety of formula (A) or (B) (wherein R11-R18 and R20-R29 are as defined in the description); and Ar is as defined...
|
|
WO/2020/108538A1 |
An RORγ inhibitor having sulfonyl structure, a preparation method thereof, and a pharmaceutical composition containing a plurality of compounds. The inhibitor has a structure represented by formula (I) or formula (V), wherein the compou...
|
|
WO/2020/111253A1 |
An organic electroluminescent element which exhibits higher performance; and a novel material which is composed of a compound represented by formula (1), and which enables the achievement of such an organic electroluminescent element. (I...
|
|
WO/2020/108117A1 |
Provided herein is a method for preparing an Escitalopram bis-hydroxynaphtoate ((S)-(+)-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)) -1, 3-dihydro-5-cyanisobenzofuranone) crystal form A. Said method is ecofriendly and non pollutive, a...
|
|
WO/2020/111251A1 |
Provided are: a high-performance organic electroluminescent device; and a compound represented by formula (1), the compound being a novel material for realizing such an organic electroluminescent device. (In formula (1), X, Ar1-Ar5, R1-R...
|
|
WO/2020/106102A1 |
The present specification relates to a compound of chemical formula 1 and an organic light emitting diode comprising same.
|
|
WO/2020/104657A1 |
The present application relates to compounds with NLRP3inhibitory activity and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present application further relates to the use of such compounds in the treatment...
|
|
WO/2020/102576A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/101563A1 |
The present disclosure relates to a method of producing monophenolicmonomers and furfural from lignocellulosic biomass beating the biomass in a solvent together with a zeolite based catalyst.
|
|
WO/2020/102574A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/101234A1 |
The present invention relates to a method for preparing furan-based compounds, comprising a step of preparing one or more furan-based compounds selected from the group consisting of 2,5-furandimethanol (FDM) and 2,5-5etrahydrofuran dimet...
|
|
WO/2020/101731A1 |
The present disclosure relates to methods, systems, and devices for extracting cannabinoids from organic matter, such as plant matters with reduced tetrahydrocannabinol (THC) and/or increased cannabidiol (CBD) content. In some embodiment...
|
|
WO/2020/094526A1 |
The present invention relates to a process for the extraction of furfural from a biphasic dehydration reaction mixture in a resource- and energy-efficient manner by the use of one or more adsorption units to increase the recovery of furf...
|
|
WO/2020/095983A1 |
It was discovered that a cyclic sulfamidate could be produced by reacting an aminoacid derivative with a cyclization reagent. In addition, it was discovered that an O-substituted serine derivative could be produced by reacting the cyclic...
|
|
WO/2020/096001A1 |
A compound represented by formula (1) (wherein R1 to R8, R10 to R19, R30 to R46, Ar, L, and *a are as defined in the description) is useful in providing an organic EL element having improved element performance.
|
|
WO/2020/095008A1 |
The invention relates to the field of producing 4-hydroxymethyl-γ-butyrolactone (2H-HBO) from levoglucosenone (LGO). More particularly, the invention concerns an eco-compatible method for synthesising 2H-HBO optionally substituted at th...
|
|
WO/2020/095031A1 |
Organosulfur compounds of formula (I), where R1 and R2 are as defined herein, and pharmaceutical compositions comprising these organosulfur compounds. Uses of the organosulfur compounds and the pharmaceutical compositions for treating in...
|
|
WO/2020/087766A1 |
A use of a benzofuran derivative represented by formula I in preparing a microbicidal and anti-inflammatory commodity. Further provided is a use of the benzofuran derivative in a microbicidal and anti-inflammatory toothpaste, wherein the...
|
|
WO/2020/091446A1 |
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound according to the present disclosure, an organic ...
|
|
WO/2020/092978A1 |
Type 3 Secretion System (T3 SS) inhibitors, tanshinones and tanshinone analogs, and methods of using the same for the treatment of disease are disclosed. The invention relates generally to antibiotic compounds and methods of treating or ...
|
|
WO/2020/087688A1 |
A method for preparing a dihydrofuran chalcone compound, the method comprising the following steps: extracting mulberry leaves by using a methanol or ethanol aqueous solution having a volume fraction of 40-100%; concentrating an extracti...
|
|
WO/2020/089138A1 |
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, to a process for manufacturing the compounds of formula (1), to intermediat...
|
|
WO/2020/092383A1 |
The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processe...
|
|
WO/2020/086728A1 |
In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/085845A1 |
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound of the present disclosure may be comprised in a light-emitting...
|
|
WO/2020/086367A1 |
Provided are novel prodrugs of esuberaprost and pharmaceutical compositions thereof, as well as methods of making and methods of using these prodrugs.
|
|
WO/2020/084094A1 |
The present invention relates to a process for preparing a nitrated compound, comprising the step of reacting a compound (A) comprising at least one substituted or unsubstituted aromatic or heteroaromatic ring, wherein said heteroaromati...
|
|
WO/2020/083327A1 |
Disclosed in the present invention is an organic compound containing a spirobifluorene structure, having a structure as represented by chemical formula (1), wherein Ar1(Ar2)N-(S1)m- and -(S2)n-NAr3(Ar4) are different, and have symmetrica...
|
